KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Operating Expenses (2016 - 2025)

Biogen has reported Operating Expenses over the past 17 years, most recently at $2.3 billion for Q4 2025.

  • Quarterly results put Operating Expenses at $2.3 billion for Q4 2025, up 7.96% from a year ago — trailing twelve months through Dec 2025 was $8.3 billion (up 7.26% YoY), and the annual figure for FY2025 was $8.3 billion, up 7.26%.
  • Operating Expenses for Q4 2025 was $2.3 billion at Biogen, up from $2.0 billion in the prior quarter.
  • Over the last five years, Operating Expenses for BIIB hit a ceiling of $2.7 billion in Q3 2023 and a floor of $1.1 billion in Q3 2022.
  • Median Operating Expenses over the past 5 years was $2.0 billion (2023), compared with a mean of $2.0 billion.
  • Biggest five-year swings in Operating Expenses: tumbled 54.28% in 2022 and later soared 134.88% in 2023.
  • Biogen's Operating Expenses stood at $2.3 billion in 2021, then fell by 16.69% to $1.9 billion in 2022, then increased by 7.96% to $2.1 billion in 2023, then increased by 3.27% to $2.2 billion in 2024, then rose by 7.96% to $2.3 billion in 2025.
  • The last three reported values for Operating Expenses were $2.3 billion (Q4 2025), $2.0 billion (Q3 2025), and $1.9 billion (Q2 2025) per Business Quant data.